AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32978076
Drug: Clarithromycin-naproxen-oseltamivir combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin-naproxen-oseltamivir combination therapy
Trial: 36455504
Drug: FTD/TPI (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTD/TPI (35 mg/m2 twice daily days 1‐5 and 8‐12, 28‐day cycle)
Trial: 32479701
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D insufficient (25(OH)D <50nmol/L)
Trial: 32479701
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D sufficient (25(OH)D ≥50nmol/L)
Trial: 36352326
Drug: Psychiatric treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychiatric treatment initiation after March 2020
Trial: 33452295
Drug: beta-blocker (timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta-blocker (timolol maleate) and/or prostaglandin analog (latanoprost)
Trial: 33947390
Drug: pemafibrate 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pemafibrate 0.1 mg/day
Trial: 33947390
Drug: pemafibrate 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pemafibrate 0.2 mg/day
Trial: 33947390
Drug: pemafibrate 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pemafibrate 0.4 mg/day
Trial: 33947390
Drug: pemafibrate (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pemafibrate (all doses)
Trial: 33250209
Drug: Eptinezumab (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eptinezumab (all doses)
Trial: 34129855
Drug: Androgen-deprivation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen-deprivation therapy (ADT) alone
Trial: 33327340
Drug: Electroacupuncture (EA),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA), administered 2 times a week for 4 weeks.
Trial: 36103719
Drug: Electrical vestibular
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Electrical vestibular stimulation (n=15) administered for 12 weeks
Trial: 34386216
Drug: Topical emollient
RxNorm normalized name: HPR Topical Emollient Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical emollient therapy with sunflower seed oil (SSO)
Trial: 34629300
Drug: Docetaxel +
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel + Metformin (D+M)
Trial: 34342746
Drug: Lurasidone (20-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone (20-120 mg/day)
Trial: 35323085
Drug: Triptorelin (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptorelin (0.1 mg subcutaneous GnRH agonist)
Trial: 35475155
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist therapy
Trial: 34087831
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of dexmedetomidine
Trial: 34087831
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of 0.9% sodium chloride solution (control)
Trial: 32799649
Drug: Cognitive Orientation
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Orientation to daily Occupational Performance approach™ (CO‐OP)
Trial: 35264213
Drug: Green-MED diet
RxNorm normalized name: acid green 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green-MED diet (supplemented with 28g/day walnuts, daily polyphenol-rich green tea, and Mankai aquatic plant)
Trial: 33186897
Drug: Collagen Peptides
RxNorm normalized name: CASTOR OIL 100 g in 100 mL TOPICAL OIL [Anyi Beauty Biotin With Collagen Peptides Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagen Peptides (15 g/day)
Trial: 33725433
Drug: High oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High oxygen concentration (100% O2, non-rebreather mask, 8 L/min)
Trial: 32004648
Drug: FMX103 1.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FMX103 1.5% topical minocycline foam
Trial: 34431238
Drug: Wait-list/no-treatment control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wait-list/no-treatment control group
Trial: 32173633
Drug: Dual trigger
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual trigger group (GnRH agonist and rHCG)
Trial: 35924398
Drug: Non-ionic colloidal
RxNorm normalized name: NON-IONIC CONTRAST MEDIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-ionic colloidal silver solution rinse for 6 months as an adjunct to standard oral hygiene regimen
Trial: 32690763
Drug: v-gel SGAD
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: v-gel SGAD
Trial: 33231778
Drug: Topical tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical tranexamic acid (TXA) applied to wound surface for 5 minutes after incision
Trial: 32076985
Drug: Individual acupuncture
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual acupuncture therapy
Trial: 32076985
Drug: Group acupuncture
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group acupuncture therapy
Trial: 35609328
Drug: FED (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FED (0.25 g·kg‐1 protein and 0.75 g·kg‐1 carbohydrate with 5% l‐[1‐13C]leucine)
Trial: 35609328
Drug: EXFED (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EXFED (0.25 g·kg‐1 protein and 0.75 g·kg‐1 carbohydrate with 5% l‐[1‐13C]leucine after resistance exercise)
Trial: 35840300
Drug: Family doctor-led
RxNorm normalized name: Doctor's Choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family doctor-led intervention including usual care, medication reminder, 4-week plan, weekly phone interview, and monthly interview.
Trial: 36207154
Drug: Active medication
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active medication (multimodal analgesic solution)
Trial: 32780742
Drug: Agent-based dynamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agent-based dynamic process with gendered status concerns
Trial: 32780742
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group of agents less influenced by relative status rank
Trial: 34861170
Drug: Pimavanserin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimavanserin (20 mg starting dosage, adjustable to 34 mg or 10 mg within the first 8 weeks, administered orally once daily)
Trial: 35859621
Drug: Amino Acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino Acid Combination (AA) (3 g of L-arginine-hydrochloride and 8 g of L-citrulline-malate)
Trial: 35859621
Drug: Green Tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green Tea Extract (GTE) (300 mg)
Trial: 33177278
Drug: Ascidian-derived plasmalogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascidian-derived plasmalogen (1 mg as plasmalogen) for 12 weeks
Trial: 33211738
Drug: Evidence-based practices
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based practices (EBPs) in dispensing OTC medications
Trial: 32929906
Drug: Percutaneous autogenous
RxNorm normalized name: Autogene cevumeran
DrugBank: Autogene cevumeran (DB17497)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous autogenous cBMA+PRP injection
Trial: 32929906
Drug: Percutaneous autogenous
RxNorm normalized name: Autogene cevumeran
DrugBank: Autogene cevumeran (DB17497)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous autogenous bone marrow blood injection (Control)
Trial: 36233611
Drug: Ellagic Acid
RxNorm normalized name: Ellagic acid
DrugBank: Ellagic acid (DB08846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ellagic Acid (500 mg orally twice a day for 12 weeks)
Trial: 34967732
Drug: Suprascapular nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suprascapular nerve block (SSNB) in combination with intra-articular corticosteroid injection (IAI)
Trial: 34967732
Drug: Intra-articular corticosteroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular corticosteroid injection (IAI) only
Trial: 33449337
Drug: ALN-EX (effervescent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALN-EX (effervescent buffered solution of 70 mg alendronate)
Trial: 33449337
Drug: ALN-T (alendronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALN-T (alendronate tablets)
Trial: 36471982
Drug: Chinese medicine
RxNorm normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese medicine as adjuvant therapy
Trial: 33934471
Drug: 4% capryloyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% capryloyl glycine and 1% glycine soy‐fermented extract cream (product A)
Trial: 33934471
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream (product B)
Trial: 34516703
Drug: Naringenin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naringenin (100 mg capsules, twice a day for 4 weeks)
Trial: 34516703
Drug: Control (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (placebo capsules, twice a day for 4 weeks)
Trial: 35733127
Drug: Transdiagnostic cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdiagnostic cognitive behavioral therapy (TCBT) - 10 sessions
Trial: 33218555
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy and rehabilitation (PTR) combined with osteopathic management (OSTEO group)
Trial: 33218555
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy and rehabilitation (PTR) only (PTR group)
Trial: 35796739
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist regimen
Trial: 35796739
Drug: Short GnRH
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short GnRH agonist regimen
Trial: 33397139
Drug: Midazolam (0.045
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.045 mg/kg)
Trial: 35298917
Drug: Levothyroxine (0.5-1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine (0.5-1.0 μg/kg bodyweight, orally once daily until the end of pregnancy)
Trial: 35298917
Drug: Placebo (orally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (orally once daily until the end of pregnancy)
Trial: 32485325
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (pharmacy liaison to promote medication adherence).
Trial: 36006011
Drug: Filgotinib vs.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filgotinib vs. intravenous vedolizumab
Trial: 36006011
Drug: Filgotinib vs.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filgotinib vs. subcutaneous vedolizumab
Trial: 34308834
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg generic solifenacin succinate tablet
Trial: 34308834
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg solifenacin succinate tablets (vesicare)
Trial: 35532908
Drug: Methylcobalamin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylcobalamin (50 mg, intramuscular injection, twice weekly for 16 weeks)
Trial: 35532908
Drug: Placebo (intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intramuscular injection, twice weekly for 16 weeks)
Trial: 34588198
Drug: Low-dose inhaled
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose inhaled corticosteroids (VDKA trial)
Trial: 35933275
Drug: Inactivated quadrivalent
RxNorm normalized name: influenza virus vaccine, inactivated quadrivalent intramuscular suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated quadrivalent influenza vaccine (IIV4) co-administered with the first dose of CoronaVac (C1 subgroup)
Trial: 35933275
Drug: Inactivated quadrivalent
RxNorm normalized name: influenza virus vaccine, inactivated quadrivalent intramuscular suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated quadrivalent influenza vaccine (IIV4) co-administered with the second dose of CoronaVac (C2 subgroup)
Trial: 35933275
Drug: CoronaVac administered
RxNorm normalized name: CoronaVac
DrugBank: CoronaVac (DB15806)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoronaVac administered 14 days after the first dose (S group)
Trial: 32598699
Drug: Mechanical bacterial
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical bacterial lysate (MBL) added to conventional therapy for COPD, 3 cycles of 10 days therapy with 20-day intervals between them.
Trial: 32598699
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy for COPD without MBL (control group).
Trial: 34379277
Drug: Multimodal strategies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal strategies including clinician hypertension group‐based trainings, monthly clinician feedback reports, and monthly meetings with practice champions
Trial: 33011586
Drug: In-person therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-person therapy
Trial: 35213754
Drug: Rumen-protected lysine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rumen-protected lysine (RPL) supplementation (80g daily from Day 21 before expected calving to parturition)
Trial: 33641259
Drug: Pharmacogenomics guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacogenomics guided treatment (n=105)
Trial: 33641259
Drug: Standard antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antidepressant treatment (n=108)
Trial: 33962901
Drug: Academy of
RxNorm normalized name: Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Academy of Nutrition and Dietetics/American Society for Parenteral and Enteral Nutrition indicators for the diagnosis of adult and pediatric malnutrition
Trial: 36191334
Drug: Any analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any analgesic administration
Trial: 36191334
Drug: Analgesic administration
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic administration in African American patients
Trial: 36191334
Drug: Analgesic administration
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic administration in White patients
Trial: 36191334
Drug: Analgesic administration
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic administration in Hispanic patients
Trial: 34001002
Drug: M207 3.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M207 3.8 mg (intracutaneous zolmitriptan)
Trial: 32412986
Drug: TFP block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TFP block with 20 ml of 0.25% bupivacaine
Trial: 36919514
Drug: d-amphetamine (AMPH;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-amphetamine (AMPH; 20 mg)
Trial: 36165603
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptives and menstrual cycle phases
Trial: 32019814
Drug: 1.8 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 µg of vitamin B12 daily for 6 months
Trial: 32019814
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of folic acid daily for 6 months
Trial: 32019814
Drug: Both vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both vitamin B12 and folic acid daily for 6 months
Trial: 33524593
Drug: Standard-volume plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-volume plasma exchange (SVPE), mean sessions 2.15 ± 1.42, median plasma volume replaced 5.049 L
Trial: 35986323
Drug: Atosiban (6.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atosiban (6.75 mg bolus intravenously 30 min before embryo transfer)
Trial: 35986323
Drug: Placebo (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline infusion)
Trial: 33887486
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of fibrosis grade and pancreatic texture
Trial: 34958809
Drug: 0.5 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 Gy single session LDRT along with standard pharmacologic therapy
Trial: 34958809
Drug: Standard pharmacologic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard pharmacologic therapy alone
Trial: 33684595
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of meropenem 3 g/24 h
Trial: 33684595
Drug: Bolus administration
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus administration of meropenem 1 g q8h
Trial: 32509290
Drug: Sunflower seed
RxNorm normalized name: SUNFLOWER SEED
DrugBank: Sunflower seed (DB10907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunflower seed oil (SSO) treatment at 3 g/kg body weight three times daily for 10 days
Trial: 32509290
Drug: Sunflower seed
RxNorm normalized name: SUNFLOWER SEED
DrugBank: Sunflower seed (DB10907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunflower seed oil (SSO) treatment
Trial: 35612684
Drug: Caffeine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (5 mg.kg-1, OP-CAF)
Trial: 32446323
Drug: Comprehensive disease-modifying
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive disease-modifying pharmacological therapy (ARNI, β blocker, MRA, SGLT2 inhibitor)
Trial: 39077886
Drug: Bimekizumab 160
RxNorm normalized name: Bimekizumab 160 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimekizumab 160 mg every four weeks
Trial: 33044249
Drug: Allogeneic pure
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic pure PRP injection (4 mL)
Trial: 33044249
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection (4 mL mixture of 1 mL of 40‐mg/mL triamcinolone acetonide and 3 mL of 2% lidocaine)
Trial: 33044249
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection (4 mL mixture)
Trial: 33922552
Drug: Fentanyl administration
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl administration
Trial: 33922552
Drug: Sevoflurane administration
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane administration
Trial: 34255767
Drug: Treatment based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment based on cerebrospinal fluid (CSF) analysis after lumbar puncture (LP)
Trial: 33685394
Drug: Topical tissue
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tissue adhesive (TA)
Trial: 35034023
Drug: Titration group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titration group (Adinox® 25 mg aspirin/200 mg dipyridamole once daily for 2 weeks, then twice daily for 2 weeks)
Trial: 35034023
Drug: Standard group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard group (Adinox® twice daily for 4 weeks)
Trial: 35034023
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Aspirin 100 mg once daily for 4 weeks)
Trial: 38841588
Drug: DAPT (Dual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAPT (Dual Antiplatelet Therapy)
Trial: 33675664
Drug: Levofloxacin administration
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin administration
Trial: 32454920
Drug: Dexmedetomidine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.5 μg/kg intravenous bolus injection for 10 min before induction of anesthesia, followed by continuous infusion of 0.2‐0.4 μg/kg/h until the end of surgery, and 0.06 μg/kg/h for 5 days after surgery)
Trial: 33203618
Drug: Oral beta
RxNorm normalized name: Cloral betaine
DrugBank: Chloral betaine (DB01494)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral beta blockade